Having established SL-176 as the most potent inhibitor of the WIP1–MDM2–p53 circuit among the compounds tested, we next investigated the anti-tumorigenic effect of SL-176 monotherapy in preclinical in vivo models of neuroblastoma and medulloblastoma. This evidence concerns the gene PPM1D and neuroblastoma.